Linked Life Data

18288408

Source:http://linkedlifedata.com/resource/pubmed/id/18288408

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2008-2-21
pubmed:abstractText
5-Fluorouracil (5-FU) is the most commonly used anticancer drug for colorectal cancer (CRC). In this study, we aimed to clarify the prognostic value of the expression of the 5-FU metabolic enzyme genes, including orptate phosphoribosyl transferase (OPRT), dihydropyrimidine dehydrogenase (DPD), thymidylate synthetase (TS) and thymidylate phosphorylate (TP) genes in CRC patients treated with oral 5-FU-based adjuvant chemotherapy. We examined 103 CRC patients with Dukes' stage B and C who underwent oral 5-FU-based adjuvant chemotherapy. Formalin-fixed, paraffin-embedded tumor specimens from primary CRC tissues were dissected by laser-captured microdissection and quantification of mRNA levels of OPRT, DPD, TS and TP were measured by real-time reverse transcription (RT) PCR. The relationship between these 5-FU metabolic enzyme gene levels and disease-free and overall survival rates were examined. The disease-free and overall survival curves of the OPRT mRNA high-expression group were significantly longer than that of the OPRT mRNA low-expression group. The disease-free and overall survival curves of the DPD mRNA high-expression group were significantly shorter than that of the DPD mRNA low-expression group. In contrast, there were no significant differences between the TS or TP mRNA high- expression and low-expression groups in the disease-free and overall survival curves. In a multivariate Cox regression analysis, it was demonstrated that the OPRT mRNA level is an independent prognostic variable for disease-free and overall survival. These results suggest that the OPRT mRNA is a useful indicator in the prediction of disease-free and overall survival in Dukes' B and C stage CRC patients treated with oral 5-FU-based adjuvant chemotherapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1021-335X
pubmed:author
pubmed:issnType
Print
pubmed:volume
19
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
729-35
pubmed:meshHeading
pubmed-meshheading:18288408-Administration, Oral, pubmed-meshheading:18288408-Adult, pubmed-meshheading:18288408-Aged, pubmed-meshheading:18288408-Aged, 80 and over, pubmed-meshheading:18288408-Antimetabolites, Antineoplastic, pubmed-meshheading:18288408-Chemotherapy, Adjuvant, pubmed-meshheading:18288408-Colorectal Neoplasms, pubmed-meshheading:18288408-Dihydrouracil Dehydrogenase (NADP), pubmed-meshheading:18288408-Fluorouracil, pubmed-meshheading:18288408-Humans, pubmed-meshheading:18288408-Middle Aged, pubmed-meshheading:18288408-Orotate Phosphoribosyltransferase, pubmed-meshheading:18288408-RNA, Messenger, pubmed-meshheading:18288408-Survival Analysis, pubmed-meshheading:18288408-Thymidine Phosphorylase, pubmed-meshheading:18288408-Thymidylate Synthase, pubmed-meshheading:18288408-Treatment Outcome
pubmed:year
2008
pubmed:articleTitle
Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
pubmed:affiliation
Department of Surgery, Teikyo University School of Medicine, Tokyo 173-0003, Japan.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't